Table 2 Comparison of participant characteristics between two COPD groups
Varibles | Group with elevated serum T-IgE (129 cases) | Group with normal serum T-IgE (144 cases) | P value |
|---|---|---|---|
Male, n(%) | 89(68.9) | 85(59.0) | 0.09 |
Age | 76(9.2,51 ~ 90) | 77(6.2,58 ~ 89) | 0.12 |
Non smokers, n(%) | 20(15.5) | 29(20.1) | 0.32 |
Smoking index of smokers (pack-yr) | 43(22,10 ~ 100) | 42(23,10 ~ 120) | 0.52 |
History of chronic cough/sputum (yr) | 19(11,2 ~ 45) | 20(12,2 ~ 50) | 0.42 |
History of dyspnea (yr) | 8.0(5.2,0.5 ~ 20) | 4.3(4.2,0 ~ 20) | <0.01 |
Ratio of dyspnea history to chronic cough/sputum history | 0.47(0.19,0.07 ~ 1) | 0.20(0.15,0 ~ 0.67) | <0.01 |
Occurrence of wheezing, n (%) | 113(87.6) | 101(70.8) | <0.01 |
FEV1/FVC% | 43(11,23 ~ 67) | 49(12,22 ~ 69) | <0.01 |
FEV1%predicted | 36(11,14 ~ 68) | 45(14,20 ~ 79) | <0.01 |
GOLD stage | Â | Â | <0.01 |
Stage II, n(%) | 20(15.5) | 53(36.8) | Â |
Stage III, n(%) | 62(48.1) | 69(47.9) | Â |
Stage IV, n(%) | 47(36.4) | 22(15.3) | Â |
Serum T-IgE (kU/L) | 818(1205,69 ~ 7420) | 28(20,2 ~ 60) | Â |
AH, n(%) | 41(31.8) | 0(0) | Â |
ABPA, n(%) | 8(6.2) | 0(0) | Â |